Certified by Founder Lodge
Foresite Capital
United States - Larkspur, California
INVESTOR
1 Disclosed Funding Rounds $30,000,000
53 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Foresite Capital is a multi-stage healthcare and life sciences investment firm with ~ $3.5B in assets under management (as of 3/31/22). The firm aims to address areas of great unmet need by f
| Company | Date | Round | Raised |
|---|---|---|---|
 Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
 Foresight Diagnostics Inc. |
April, 28 ,2023 | Series B | $58,750,000 |
 Evonetix Ltd |
February, 10 ,2023 | Series B | $24,000,000 |
 Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
 Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
 Thyme Care |
August, 22 ,2023 | Series B | $60,000,000 |
 DNAnexus |
June, 09 ,2022 | Unknown | $100,000,000 |
 FOLX Health |
October, 17 ,2022 | Series B | $30,000,000 |
 Latigo Biotherapeutics, Inc. |
February, 15 ,2024 | Series A | $135,000,000 |
 Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
 Mirvie |
May, 17 ,2022 | Series B | $60,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Foresight Diagnostics Inc. |
April, 28 ,2023 | Series B | $58,750,000 |
| Evonetix Ltd |
February, 10 ,2023 | Series B | $24,000,000 |
 FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
| Thyme Care |
August, 22 ,2023 | Series B | $60,000,000 |
| DNAnexus |
June, 09 ,2022 | Unknown | $100,000,000 |
 Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
| Latigo Biotherapeutics, Inc. |
February, 15 ,2024 | Series A | $135,000,000 |
| Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| Mirvie |
May, 17 ,2022 | Series B | $60,000,000 |
| Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
| Foresight Diagnostics Inc. |
April, 28 ,2023 | Series B | $58,750,000 |
| Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
 Candid Therapeutics |
September, 10 ,2024 | Unknown | $370,000,000 |
| Thyme Care |
August, 22 ,2023 | Series B | $60,000,000 |
| Latigo Biotherapeutics, Inc. |
February, 15 ,2024 | Series A | $135,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
 Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
 Pleno Inc. |
December, 13 ,2024 | Series B | $25,000,000 |
| Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
| Candid Therapeutics |
September, 10 ,2024 | Unknown | $370,000,000 |
| Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
| Latigo Biotherapeutics, Inc. |
February, 15 ,2024 | Series A | $135,000,000 |
| Candid Therapeutics |
September, 10 ,2024 | Unknown | $370,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| FogPharma |
March, 05 ,2024 | Series E | $145,000,000 |
| Pleno Inc. |
December, 13 ,2024 | Series B | $25,000,000 |
| Pleno Inc. |
December, 13 ,2024 | Series B | $25,000,000 |
 Avenzo Therapeutics |
September, 23 ,2025 | Series B | $60,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
| Element Biosciences |
July, 12 ,2024 | Series D | $277,000,000 |
| Candid Therapeutics |
September, 10 ,2024 | Unknown | $370,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Pleno Inc. |
December, 13 ,2024 | Series B | $25,000,000 |
| Avenzo Therapeutics |
September, 23 ,2025 | Series B | $60,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
